peptide hormone raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-28 and is reviewed periodically as new material appears.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
=== Single-atom wave propagation === Electron waves in graphene propagate within a single-atom layer, making them sensitive to the proximity of other materials such as high-κ dielectrics, superconductors, and ferromagnets.
110 (7): 955–963. doi:10.1172/JCI15918. PMC 151154. PMID 12370273. Weening, Jan J.; d'Agati, Vivette D.; Schwartz, Melvin M.; Seshan, Surya V.; Alpers, Charles E.; Appel, Gerald B.; Balow, James E.; Bruijn, J.A.N. A.; Cook, Terence; Ferrario, Franco; Fogo, Agnes B.; Ginzler, Ellen M.; Hebert, L.E.E.; Hill, Gary; Hill, Prue; Jennette, J. Charles; Kong, Norella C.; Lesavre, Philippe; Lockshin, Michael; Looi, Lai-Meng; Makino, Hirofumi; Moura, Luiz A.; Nagata, Michio; International Society of Nephrology Working Group on the Classification of Lupus Nephritis; Renal Pathology Society Working Group on the Classification of Lupus Nephritis (2004). "The classification of glomerulonephritis in systemic lupus erythematosus revisited". Kidney International. 65 (2): 521–530. doi:10.1111/j.1523-1755.2004.00443.x. hdl:20.500.12648/8230. PMID 14717922. d'Agati, Vivette D.; Fogo, Agnes B.; Bruijn, Jan A.; Jennette, J.Charles (2004). "Pathologic classification of focal segmental glomerulosclerosis: A working proposal". American Journal of Kidney Diseases. 43 (2): 368–382. doi:10.1053/j.ajkd.2003.10.024. PMID 14750104. Jennette, J. C.; Falk, R. J.; Bacon, P. A.; Basu, N.; Cid, M. C.; Ferrario, F.; Flores-Suarez, L. F.; Gross, W. L.; Guillevin, L.; Hagen, E. C.; Hoffman, G. S.; Jayne, D. R.; Kallenberg, C. G. M.; Lamprecht, P.; Langford, C. A.; Luqmani, R. A.; Mahr, A. D.; Matteson, E. L.; Merkel, P. A.; Ozen, S.; Pusey, C. D.; Rasmussen, N.; Rees, A. J.; Scott, D. G. I.; Specks, U.; Stone, J. H.; Takahashi, K.; Watts, R. A. (2013).
==== Scoring binding predictions ==== Protein design energy functions must be adapted to score binding predictions because binding involves a trade-off between the lowest-energy conformations of the free proteins (EP and EL) and the lowest-energy conformation of the bound complex (EPL):
== History == Historically, baclofen was designed as a drug for treating epilepsy. It was first synthesized at Ciba-Geigy by the Swiss chemist Heinrich Keberle in 1962. Its effect on epilepsy was ineffective, but it was found that in certain people, spasticity decreased. In 1971, it was introduced as a treatment for certain form of spasticity. It was approved by the US Food and Drug Administration (FDA) in 1977. Intrathecal baclofen was first introduced in 1984 to treat severe spinal spasticity. This administration route aimed to avoid supraspinal side effects.
Sources: en.wikipedia.org
Tang, Velcro, and Teflon were not spun off from technology originally developed by NASA for spaceflight, though many other products (such as memory foam and space blankets) were. The Sun is not yellow; rather, it emits light across the full spectrum of visible colors, and this combined light appears white when outside of Earth's atmosphere. Earth's atmosphere scatters shorter wavelengths of light, particularly blues and violets, more than longer wavelengths like reds and yellows, and this scattering is why the Sun appears yellow during the day or orange or red during sunrise and sunset. The scattered blue/violet light, appearing to come from all directions, is what makes the rest of the sky look blue. The Great Wall of China is not the only human-made object visible from space or from the Moon. None of the Apollo astronauts reported seeing any specific human-made object from the Moon, and even Earth-orbiting astronauts can see it only with magnification. City lights, however, are easily visible on the night side of Earth from orbit. The Big Bang model does not fully explain the origin of the universe. It does not describe how energy, time, and space were caused, but rather it describes the emergence of the present universe from an ultra-dense and high-temperature initial state.
=== Brand names === In May 2015, a formulation of paliperidone palmitate was approved by the U.S. Food and Drug Administration under the brand name Invega Trinza. A similar prolonged release suspension was approved in 2016 by the European Medicines Agency originally under the brand name Paliperidone Janssen, later renamed to Trevicta. In September 2021, a newer formulation of paliperidone palmitate, Invega Hafyera, was approved by the US FDA.
== Interactions == MECP2 has been shown to interact with SKI protein and Nuclear receptor co-repressor 1. In neuronal cells the MECP2 mRNA is thought to interact with miR-132, which silences the expression of the protein. This forms part of a homeostatic mechanism that could regulate MECP2 levels in the brain. MECP2 has been shown to be phosphorylated by MSK1 following BDNF induction.
Sources: en.wikipedia.org
=== Recurring === MC Lyte as Kai Owens, Mona's boss Obba Babatundé as Charles Thorne, Mona and Dee Dee's father; ex-husband of Phyllis and current husband of Big Dee Dee. Estelle Harris as Sophie, Mona's grandmother (and Phyllis' mother), who is white and Jewish. Corey Holcomb as Chauncey, Spencer's cousin Joey Lawrence as Brett Mahoney Coby Bell as Glen Stallworth Keith Robinson as Neil Crawford Michelle Williams as Naomi Dawson Penny Bae Bridges as Young Mona Gabby Soleil as Young Dee Dee Yvette Nicole Brown as Ceci Louis Gossett Jr. as Ray Willis, Spencer's father. Suzy Nakamura as Tina Lamman Rucker as Chase Charles Divins as Lorenzo Rowena King as Camille
=== Metabolic disorders === Preclinical evidence from animal models suggests that S. boulardii supplementation may reduce body weight in the context of type 2 diabetes; however, clinical evidence in humans is currently lacking. Additional studies in diet-induced obesity models further support these findings, showing that S. boulardii can attenuate weight gain, reduce food intake, and increase energy expenditure. These effects are accompanied by coordinated changes in gut microbiota composition, microbial metabolic activity, and host immune signaling, including reduced inflammatory pathways (e.g., TNFα/NF-κB) and shifts in metabolites linked to metabolic regulation, suggesting modulation of the gut–immune–metabolic axis.
A large meta-analysis has shown that white adipose tissue cell size is dependent on measurement methods, adipose tissue depots, age, and body mass index; for the same degree of obesity, increases in fat cell size were also associated with the dysregulations in glucose and lipid metabolism.
is called the rate of shear deformation or shear velocity, and is the derivative of the fluid speed in the direction parallel to the normal vector of the plates (see illustrations to the right). If the velocity does not vary linearly with
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.